NYSE:TAROTaro Pharmaceutical Industries Stock Price, Forecast & News

Taro Pharmaceutical Industries' stock was trading at $64.44 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TARO stock has increased by 5.4% and is now trading at $67.90. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Taro Pharmaceutical Industries.

Taro Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Taro Pharmaceutical Industries.

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) posted its quarterly earnings results on Tuesday, May, 19th. The company reported $1.42 earnings per share for the quarter, missing the consensus estimate of $1.53 by $0.11. The firm had revenue of $174.94 million for the quarter, compared to the consensus estimate of $168.25 million. Taro Pharmaceutical Industries had a return on equity of 11.94% and a net margin of 37.88%. View Taro Pharmaceutical Industries' earnings history.

1 Wall Street analysts have issued 1 year price objectives for Taro Pharmaceutical Industries' shares. Their forecasts range from $96.00 to $96.00. On average, they expect Taro Pharmaceutical Industries' share price to reach $96.00 in the next twelve months. This suggests a possible upside of 41.4% from the stock's current price. View analysts' price targets for Taro Pharmaceutical Industries.

News coverage about TARO stock has been trending positive this week, according to InfoTrie. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Taro Pharmaceutical Industries earned a media sentiment score of 2.4 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutTaro Pharmaceutical Industries.

Taro Pharmaceutical Industries saw a decrease in short interest in the month of April. As of April 30th, there was short interest totaling 131,900 shares, a decrease of 13.0% from the April 15th total of 151,600 shares. Based on an average trading volume of 49,900 shares, the days-to-cover ratio is presently 2.6 days. Approximately 1.5% of the shares of the stock are short sold. View Taro Pharmaceutical Industries' Current Options Chain.

Some companies that are related to Taro Pharmaceutical Industries include Ono Pharmaceutical (OPHLF), Horizon Therapeutics (HZNP), Mylan (MYL), Elanco Animal Health (ELAN), Dr.Reddy's Laboratories (RDY), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), ACADIA Pharmaceuticals (ACAD), Bausch Health Companies (BHC), Ascendis Pharma A/S (ASND), Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR), Myokardia (MYOK), Forty Seven (FTSV) and Emergent Biosolutions (EBS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Taro Pharmaceutical Industries investors own include Gilead Sciences (GILD), Broadcom (AVGO), Bausch Health Companies (BHC), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Skyworks Solutions (SWKS), GW Pharmaceuticals PLC- (GWPH), Jazz Pharmaceuticals (JAZZ), Mallinckrodt (MNK) and Novo Nordisk A/S (NVO).

Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."

Taro Pharmaceutical Industries' stock is owned by a number of institutional and retail investors. Top institutional investors include Krensavage Asset Management LLC (1.27%), Acadian Asset Management LLC (0.92%), APG Asset Management N.V. (0.57%), Invesco Ltd. (0.40%), APG Asset Management N.V. (0.34%) and APG Asset Management N.V. (0.34%).

TARO stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., APG Asset Management N.V., Invesco Ltd., Bank of New York Mellon Corp, JPMorgan Chase & Co., Parametric Portfolio Associates LLC, Jane Street Group LLC, and CLARET ASSET MANAGEMENT Corp.

TARO stock was bought by a variety of institutional investors in the last quarter, including Krensavage Asset Management LLC, Citigroup Inc., Acadian Asset Management LLC, AXA, Deutsche Bank AG, APG Asset Management N.V., Morgan Stanley, and Empirical Finance LLC.

Shares of TARO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TARO stock can currently be purchased for approximately $67.90.

Taro Pharmaceutical Industries has a market capitalization of $2.60 billion and generates $644.77 million in revenue each year. The company earns $244.24 million in net income (profit) each year or $6.35 on an earnings per share basis. Taro Pharmaceutical Industries employs 1,464 workers across the globe.

The official website for Taro Pharmaceutical Industries is www.taro.com.

Taro Pharmaceutical Industries' mailing address is 14 HAKITOR ST PO BOX 10347, HAIFA BAY L3, 10532. The company can be reached via phone at 972-4847-5700 or via email at [email protected]